Neo-DCVac is able to safely reinduce objective responses to immunotherapy in patients whose disease had relapsed after previous single-agent PD-1 monoclonal antibody treatment, suggesting that Neo-DCVac has important implications in solid tumor oncology beyond NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.